Tianda Pharmaceuticals (00455) disclosed that as of January 31, 2026, its authorized share capital remained at 4,000,000,000 ordinary shares with a par value of HKD 0.1 each, totaling HKD 400,000,000. The number of issued shares stood at 2,150,041,884, and no treasury shares were recorded.

The company confirmed compliance with the public float requirement, which is set at 25% of the total number of issued shares excluding treasury shares.

Under the current share option scheme, no share options were exercised in January. The data showed zero new shares issued and zero treasury shares transferred, while up to 215,004,188 shares may be issued upon exercise of the scheme’s options at the end of the month.